Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04842747 · ClinicalTrials.gov registry record · Phase 3
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
A Phase 3 study of SARS-CoV Infection, sponsored by Veru.
- Completed
- Registry status
- Phase 3
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT04842747: Completed Phase 3 study of SARS-CoV Infection, sponsored by Veru.
NCT04842747 is a Phase 3 study of SARS-CoV Infection that has completed, run by Veru. The registered enrollment target is 204 participants, below the 3,492-participant average among 12 other SARS-CoV Infection trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04842747, a Phase 3 study of SARS-CoV Infection, has completed, sponsored by Veru.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
Primary Outcome
Efficacy of VERU-111 in the treatment of SARS-Cov- 2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
Conditions Studied
Interventions
- DRUG VERU-111
Study Locations (20)
New Jersey
- Inspira Medical Center Mullica Hill - Mullica Hill
- Holy Name Medical Center, Institute for Clinical Research - Teaneck
- Inspira Medical Center - Vineland
Tennessee
- The Stern Cardiovascular Foundation, Inc. - Germantown
- Regional One Health - Memphis
- North Knoxville Medical Center - Powell
California
- Velocity Clinical Research - Chula Vista
- Velocity Clinical Research - San Diego - La Mesa
Florida
- Westchester General Hospital, Research Department - Miami
- James A. Haley Veterans Hospital - Tampa
Minnesota
- Methodist Hospital - Saint Louis Park
- Regions Hospital - Saint Paul
North Carolina
- University of North Carolina - Chapel Hill
- Atrium Health Carolinas Medical Center - Charlotte
Texas
- HD Research (Memorial Hermann - Memorial City Medical Center) - Houston
- HD Research (Memorial Hermann Southeast Hospital) - Houston
Arizona
- Honor Health - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-07-06 |
| Phase | Phase 3 |
What the finished NCT04842747 record still lists
NCT04842747 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 3,492-participant average among 12 other SARS-CoV Infection trials with a reported enrollment target (94% lower).
The record links to 1 condition, with SARS-CoV Infection appearing as the primary indexed condition, and to 1 intervention - of which VERU-111 is the first listed.
NCT04842747 names 20 study sites across 11 states, led by New Jersey, Tennessee, California.
Frequently Asked Questions
What is clinical trial NCT04842747 about?
NCT04842747 is a clinical study titled "VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study". To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
What is the current status of trial NCT04842747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2021-05-18. Estimated completion is 2022-07-06.
What conditions does trial NCT04842747 study?
This clinical trial studies the following conditions: SARS-CoV Infection.
What interventions are being tested in trial NCT04842747?
The interventions under investigation include: VERU-111 (DRUG).
Who is sponsoring clinical trial NCT04842747?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04842747 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04842747's enrollment target sits among peer trials
204 8th of 12 higher than 5 of 12 other SARS-CoV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS-CoV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
KIDney Injury in Times of COVID-19 (KIDCOV)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI